Marketdash
Back to News

FibroBiologics Expands Patent Portfolio With New Orthopedic Application

MarketDash Editorial Team
9 hours ago
FibroBiologics submitted a new patent application covering its fibroblast-based platform for treating disc degeneration, cartilage damage, and joint restoration, building on a portfolio of over 270 patents.

FibroBiologics, Inc. (FBLG) took another step in building out its intellectual property fortress on Wednesday, filing a new patent application with the U.S. Patent and Trademark Office that covers its fibroblast-based therapy platform for orthopedic and musculoskeletal conditions.

The application specifically targets degenerative disc repair, cartilage repair, and joint restoration. Think of it as addressing the wear-and-tear problems that plague aging joints and spines, but with a cell-based approach rather than traditional surgical interventions.

If granted, the patent would strengthen protections around the company's fibroblast technology, which leverages fibroblast cells, spheroids, and fibroblast-differentiated chondrocyte spheroids to support both structural and functional repair in orthopedic tissues. For context, fibroblasts are cells that help form connective tissue, making them a logical candidate for repairing damaged structural components in the body.

Preclinical studies show that these fibroblast-based constructs and chondrocyte spheroids can integrate with native tissue, promote extracellular matrix remodeling, and encourage regeneration in models of disc degeneration and joint degeneration. That's the kind of data you want to see before moving into human trials.

FibroBiologics now holds over 270 U.S. and international issued patents and pending applications across a diverse range of clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.

Recent Developments

The patent filing comes on the heels of several corporate milestones. In November, FibroBiologics closed a registered direct offering of 4.48 million shares at $0.335 per share, bringing in gross proceeds of approximately $1.5 million. The company also offered unregistered warrants to purchase up to an aggregate of 4.48 million shares at an exercise price of $0.335 per share.

Also in November, the company received regulatory approvals in Australia for a Phase 1/2 trial evaluating CYWC628 for refractory diabetic foot ulcers. The approval enables enrollment of 120 patients. CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy designed for wound healing.

Price Action: FBLG stock was up 13.61% at $0.335 on Wednesday.

Back to News

FibroBiologics Expands Patent Portfolio With New Orthopedic Application

MarketDash Editorial Team
9 hours ago
FibroBiologics submitted a new patent application covering its fibroblast-based platform for treating disc degeneration, cartilage damage, and joint restoration, building on a portfolio of over 270 patents.

FibroBiologics, Inc. (FBLG) took another step in building out its intellectual property fortress on Wednesday, filing a new patent application with the U.S. Patent and Trademark Office that covers its fibroblast-based therapy platform for orthopedic and musculoskeletal conditions.

The application specifically targets degenerative disc repair, cartilage repair, and joint restoration. Think of it as addressing the wear-and-tear problems that plague aging joints and spines, but with a cell-based approach rather than traditional surgical interventions.

If granted, the patent would strengthen protections around the company's fibroblast technology, which leverages fibroblast cells, spheroids, and fibroblast-differentiated chondrocyte spheroids to support both structural and functional repair in orthopedic tissues. For context, fibroblasts are cells that help form connective tissue, making them a logical candidate for repairing damaged structural components in the body.

Preclinical studies show that these fibroblast-based constructs and chondrocyte spheroids can integrate with native tissue, promote extracellular matrix remodeling, and encourage regeneration in models of disc degeneration and joint degeneration. That's the kind of data you want to see before moving into human trials.

FibroBiologics now holds over 270 U.S. and international issued patents and pending applications across a diverse range of clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.

Recent Developments

The patent filing comes on the heels of several corporate milestones. In November, FibroBiologics closed a registered direct offering of 4.48 million shares at $0.335 per share, bringing in gross proceeds of approximately $1.5 million. The company also offered unregistered warrants to purchase up to an aggregate of 4.48 million shares at an exercise price of $0.335 per share.

Also in November, the company received regulatory approvals in Australia for a Phase 1/2 trial evaluating CYWC628 for refractory diabetic foot ulcers. The approval enables enrollment of 120 patients. CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy designed for wound healing.

Price Action: FBLG stock was up 13.61% at $0.335 on Wednesday.